Eli Lilly has to wait a while longer for FDA verdict
Partners Eli Lilly and Incyte will have to wait until Q3 to find out whether the US health authorities can approve their drug Oluminant as a treatment for atopic dermatitis.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly's application to get approval for the drug Olumiant, which treats atopic dermatitis in adults, according to an Eli Lilly press announcement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly surpasses Novo's golden diabetes drug
For subscribers
-go.jpg)
